Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04246372 · ClinicalTrials.gov registry record · Phase 2
Tofacitinib for Immune Skin Conditions in Down Syndrome
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT04246372 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 47 participants.
The verdict
NCT04246372, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions. The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug known to block IFN signaling, in adolescents and adults with DS and an autoimmune and/or autoinflammatory skin condition. Investigators will also measure the impact of interferon inhibition on a variety of molecular markers, as well as the cognitive abilities and quality of life of participants.
Interventions
- DRUG Tofacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-10-21 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04246372
The ClinicalTrials.gov registry entry for NCT04246372 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tofacitinib is the first listed.
NCT04246372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04246372 about?
NCT04246372 is a clinical study titled "Tofacitinib for Immune Skin Conditions in Down Syndrome". People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions. The study evaluates ...
What is the current status of trial NCT04246372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2020-10-21. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT04246372?
The interventions under investigation include: Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT04246372?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.